Adicet Bio CMO granted 72,555 stock options

Adicet Bio Chief Medical Officer Julia D. Maltzman was granted stock options covering 72,555 shares of Common Stock.

Rhea-AI Filing Summary

Adicet Bio Chief Medical Officer Julia D. Maltzman was granted stock options covering 72,555 shares of Common Stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. This is a compensation-related award rather than an open-market share purchase.

The filing shows these are held directly and represent 72,555 option shares following the transaction. According to the terms, one forty-eighth of the options vest monthly over 48 months from the grant date, as long as she continues her service with the company.

Insider Trade Summary

Grant/Award: 72,555 shares

Grant/Award 1 txn

Insider Maltzman Julia D.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	72,555	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 72,555 contracts (Direct)

Footnotes (1)

1. F1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Adicet Bio (ACET) disclose about Julia Maltzman in this Form 4?

Adicet Bio reported that Chief Medical Officer Julia D. Maltzman received a grant of stock options for 72,555 shares of Common Stock at a $6.81 exercise price, expiring March 24, 2036, as part of her compensation.

How many Adicet Bio (ACET) options did Julia Maltzman acquire and at what price?

Julia D. Maltzman acquired stock options covering 72,555 shares of Adicet Bio Common Stock. The options have an exercise price of $6.81 per share, meaning she can buy shares at that price once the options vest and are exercised.

Is Julia Maltzman’s Adicet Bio (ACET) Form 4 a stock purchase or an option grant?

The Form 4 reflects an option grant, not an open-market stock purchase. Maltzman received stock options as a compensation award, giving her the right to buy 72,555 shares at $6.81 per share in the future, subject to vesting.

What are the vesting terms of Julia Maltzman’s Adicet Bio (ACET) stock options?

The options vest in equal monthly installments over four years. Specifically, 1/48th of the 72,555 option shares vests on each monthly anniversary of the grant date, provided she maintains a service relationship with Adicet Bio on each applicable vesting date.

When do Julia Maltzman’s Adicet Bio (ACET) stock options expire?

The granted stock options expire on March 24, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Adicet Bio Common Stock at the $6.81 exercise price.

How many Adicet Bio (ACET) options does Julia Maltzman hold after this transaction?

Following this transaction, the filing shows Julia D. Maltzman holding 72,555 stock options directly. These options correspond to 72,555 underlying shares of Adicet Bio Common Stock, all subject to the four-year monthly vesting schedule described in the award terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maltzman Julia D.

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.81	03/25/2026		A		72,555		(1)	03/24/2036	Common Stock	72,555	$0.00	72,555	D

Explanation of Responses:

1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)